AVBP
Price
$23.27
Change
-$0.36 (-1.52%)
Updated
Jun 13 closing price
Capitalization
796.13M
60 days until earnings call
ERAS
Price
$1.48
Change
-$0.05 (-3.27%)
Updated
Jun 13 closing price
Capitalization
419.27M
54 days until earnings call
Interact to see
Advertisement

AVBP vs ERAS

Header iconAVBP vs ERAS Comparison
Open Charts AVBP vs ERASBanner chart's image
ArriVent BioPharma
Price$23.27
Change-$0.36 (-1.52%)
Volume$441.32K
Capitalization796.13M
Erasca
Price$1.48
Change-$0.05 (-3.27%)
Volume$1.46M
Capitalization419.27M
AVBP vs ERAS Comparison Chart
Loading...
AVBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AVBP vs. ERAS commentary
Jun 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AVBP is a Buy and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 15, 2025
Stock price -- (AVBP: $23.27 vs. ERAS: $1.48)
Brand notoriety: AVBP and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AVBP: 177% vs. ERAS: 97%
Market capitalization -- AVBP: $796.13M vs. ERAS: $419.27M
AVBP [@Biotechnology] is valued at $796.13M. ERAS’s [@Biotechnology] market capitalization is $419.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.9B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AVBP’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • AVBP’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, AVBP is a better buy in the long-term than ERAS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AVBP’s TA Score shows that 5 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • AVBP’s TA Score: 5 bullish, 3 bearish.
  • ERAS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AVBP is a better buy in the short-term than ERAS.

Price Growth

AVBP (@Biotechnology) experienced а -1.06% price change this week, while ERAS (@Biotechnology) price change was -7.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.63%. For the same industry, the average monthly price growth was +13.05%, and the average quarterly price growth was +4.06%.

Reported Earning Dates

AVBP is expected to report earnings on Aug 13, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-0.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AVBP($796M) has a higher market cap than ERAS($419M). AVBP YTD gains are higher at: -12.650 vs. ERAS (-41.036). AVBP has higher annual earnings (EBITDA): -140.41M vs. ERAS (-150.24M). ERAS has more cash in the bank: 305M vs. AVBP (176M). AVBP has less debt than ERAS: AVBP (138K) vs ERAS (50.8M). AVBP (0) and ERAS (0) have equivalent revenues.
AVBPERASAVBP / ERAS
Capitalization796M419M190%
EBITDA-140.41M-150.24M93%
Gain YTD-12.650-41.03631%
P/E RatioN/AN/A-
Revenue00-
Total Cash176M305M58%
Total Debt138K50.8M0%
TECHNICAL ANALYSIS
Technical Analysis
AVBPERAS
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
N/A
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AVBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SECIX45.21N/A
N/A
NAA Large Cap Value A
IRLUX42.33-0.47
-1.10%
Voya Russell Large Cap Index Port S2
BRUDX16.00-0.19
-1.17%
MFS Blended Research Value Equity A
JDCRX43.86-0.55
-1.24%
Janus Henderson Forty R
GSRKX19.62-0.25
-1.26%
Goldman Sachs International Eq Inc R

AVBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, AVBP has been loosely correlated with ETNB. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AVBP jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVBP
1D Price
Change %
AVBP100%
-1.52%
ETNB - AVBP
45%
Loosely correlated
+8.21%
COGT - AVBP
44%
Loosely correlated
-1.94%
ERAS - AVBP
44%
Loosely correlated
-3.27%
ORIC - AVBP
43%
Loosely correlated
-0.41%
KYMR - AVBP
42%
Loosely correlated
-0.70%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-3.27%
RVMD - ERAS
57%
Loosely correlated
-1.26%
XNCR - ERAS
57%
Loosely correlated
-2.55%
LRMR - ERAS
52%
Loosely correlated
-1.03%
APGE - ERAS
52%
Loosely correlated
+6.26%
IMNM - ERAS
51%
Loosely correlated
-6.03%
More